A retrospective real-world study to assess clinical outcomes of Baricitinib for treatment of rheumatoid arthritis using data from British Society for Rheumatology Biologics Registry – Rheumatoid Arthritis (BSRBR-RA)
Latest Information Update: 20 Nov 2020
At a glance
- Drugs Baricitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms BSRBR-RA Registry
- 20 Nov 2020 New trial record
- 19 Nov 2020 Results of first follow-up presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research